Quick Facts
| Property | Value |
|---|---|
| Category | Growth Hormone Secretagogue |
| Risk Level | Moderate/High |
| Administration | Subcutaneous Injection |
| Typical Frequency | 1–3 Times Daily |
| Estimated Half-Life | Short Plasma Half-Life |
| Primary Research Interest | Growth Hormone Release / Recovery / Performance Support |
This material is provided strictly for educational and informational purposes related to peptide research and growth hormone signaling compounds. Hexarelin is a biologically active growth hormone secretagogue capable of significantly altering growth hormone, cortisol, prolactin, and metabolic signaling pathways. Information presented here should not be interpreted as medical advice, treatment recommendations, or encouragement of unsupervised use.
1. Reconstitution Guide
- Vial Size: 10 mg
- Dilutant Type: BAC Water
- Amount of Dilutant Added: 3 mL
- Final Concentration: 3.33 mg/mL
At this concentration:
• 100 mcg = 0.030 mL (3.0 units)
• 300 mcg = 0.090 mL (9.0 units)
2. Route of Administration
Hexarelin is most commonly administered as a subcutaneous injectable growth hormone secretagogue.
- Primary Route: SubQ Injection
- Preferred Timing: Commonly administered in fasted states
- Administration Notes: Frequently researched in conjunction with GHRH analogs and recovery-focused protocols
3. Typical Research Protocols
- Product Strength: 3.33 mg/mL
- Typical Delivered Amount: 100–300 mcg per dose
- Frequency: 1–3 times daily
- Cycle Length: 4–8 weeks on / 2–4 weeks off
- Special Notes: Hexarelin is commonly discussed as one of the most potent GHRP-class secretagogues, but it may also produce faster receptor desensitization compared to milder alternatives. Researchers frequently emphasize shorter cycle lengths and periodic breaks to help maintain responsiveness. Compared to GHRP-6, Hexarelin is often described as producing less appetite stimulation while potentially generating stronger growth hormone release signaling. Because Hexarelin may significantly influence cortisol, prolactin, and cardiovascular signaling pathways, conservative dosing and careful monitoring are commonly advised.
4. Summary
Hexarelin is an experimental growth hormone releasing peptide researched for its potential effects on pulsatile growth hormone release, recovery enhancement, and anabolic support pathways.
Research interest in Hexarelin commonly centers around recovery optimization, growth hormone signaling, performance-oriented applications, and tissue-repair support.
5. Mechanism of Action
Hexarelin functions by stimulating ghrelin receptors and influencing pulsatile growth hormone release pathways.
- Growth hormone release signaling
- Ghrelin receptor activation
- Potential IGF-1 enhancement
- Recovery signaling support
- Metabolic pathway modulation
- Possible anabolic support signaling
The peptide is commonly researched as part of advanced growth hormone optimization protocols.
6. Potential Benefits
- Potential increase in growth hormone signaling
- Enhanced recovery support
- Possible sleep-quality improvements
- Potential body composition support
- Possible connective tissue recovery support
- Potential synergistic effects with GHRH analogs
7. Potential Risks / Side Effects
Moderate/High
- Water retention
- Elevated cortisol signaling
- Elevated prolactin signaling
- Numbness or tingling
- Fatigue
- Potential insulin sensitivity changes
- Possible receptor desensitization with prolonged use
8. Half-Life
Hexarelin is commonly discussed as having a relatively short plasma half-life.
However, downstream growth hormone and IGF-1 signaling effects may persist considerably longer than measurable plasma concentrations.
9. Storage Information
- Store refrigerated before and after reconstitution
- Protect from direct light exposure
- Avoid repeated freeze-thaw cycles
- Maintain sterile handling practices during preparation
10. Contraindications / Warnings
- Active cancer concerns
- Uncontrolled diabetes
- Pregnancy or breastfeeding
- Known hypersensitivity to peptide compounds
- Use alongside multiple hormone-modulating compounds without supervision
11. Research References
- PubMed
- NIH Publications
- Endocrinology literature
- Peer-reviewed growth hormone and metabolism journals
CKF Tide Tables 